Skip to main content

Table 1 Characteristics of patients enrolled in the study

From: Relevance of internal time and circadian robustness for cancer patients

Age 63 y.o. (range: 37 – 78)
Sex Male 11
Female 13
Primary Tumor Colon or rectal 21
Pancreas 2
Esophagus/cardia 1
Number of metastatic sites 0 3
1 9
2 3
≥3 9
WHO-PS 0 18
1 6
2 0
Number of prior CT lines 0 7
1 2
2 6
≥3 9
CT regimen Chrono FLO 1 3
+ CETUXIMAB 1
+ DOCETAXEL 1
Chrono IF 1 1
Chrono IFL / 4
+ BEVACIZUMAB 2
+ BEVACIZUMAB + PANITUMUMAB 2
Chrono IFLO 9 16
+ CETUXIMAB 6
+ BEVACIZUMAB 1
  1. All information was collected before the patients’ inclusion in the study and refers to their previous medical history. Age is expressed as median and range. CT regimen is highlighted in bold. Additional chemotherapy drugs added to the protocol have been marked with (+), whenever necessary
  2. WHO-PS: Performance Status according to the classification of the World Health Organization
  3. CT regimen: protocol followed for chemotherapy treatment. For details, please see the material and methods section